Systems Biology Ireland

ucd.ie

SBI established in 2009 under the Science Foundation Ireland CSET programme has successfully developed an integrated mathematical modelling and experimental research programme focusing on the design of new therapeutic approaches to cancer, degenerative and inflammatory diseases based on a systems level, mechanistic understanding of cellular signal transduction networks. SBI is one of the few centres in Europe with the necessary in house expertise, technologies and capabilities to apply systems biology approaches to mammalian models. It’s recognition internationally within the field of systems biology led to the Centre’s invited participation in three large European funded consortia initiatives in 2012 namely the ITFoM, CASyM and ISBE, the last of which is included on the ESFRI 2010 Roadmap.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

UNITED HEALTH FOUNDATION PARTNERS WITH HARRIS-STOWE STATE UNIVERSITY TO CREATE NEW BIOINFORMATICS PROGRAM

Harris-Stowe State University, United Health Foundation | November 20, 2021

news image

The United Health Foundation, the philanthropic foundation of UnitedHealth Group (NYSE: UNH), has awarded a $2 million, three-year grant to Harris-Stowe State University to create a bioinformatics program for undergraduate students at the historically Black university located in St. Louis. Bioinformatics is an emerging field that combines science, physics, math and biology to aid in the diagnosis, treatment and discovery of new therapeutic advancements. An example of bioinformatics is the use of...

Read More

Cell and Gene Therapy

ISOPLEXIS ACQUIRED A LARGE PORTFOLIO OF DNA AND RNA SEQUENCING TO ENABLE INTEGRATED SINGLE-CELL SEQUENCING AND PROTEOMIC SOLUTIONS

IsoPlexis | May 26, 2021

news image

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadma...

Read More

Medical

INVEST ONTARIO SUPPORTS NEW BIOMANUFACTURING FACILITY IN HAMILTON

Invest Ontario | April 01, 2022

news image

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Ha...

Read More

Cell and Gene Therapy

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

news image

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More
news image

Medical

UNITED HEALTH FOUNDATION PARTNERS WITH HARRIS-STOWE STATE UNIVERSITY TO CREATE NEW BIOINFORMATICS PROGRAM

Harris-Stowe State University, United Health Foundation | November 20, 2021

The United Health Foundation, the philanthropic foundation of UnitedHealth Group (NYSE: UNH), has awarded a $2 million, three-year grant to Harris-Stowe State University to create a bioinformatics program for undergraduate students at the historically Black university located in St. Louis. Bioinformatics is an emerging field that combines science, physics, math and biology to aid in the diagnosis, treatment and discovery of new therapeutic advancements. An example of bioinformatics is the use of...

Read More
news image

Cell and Gene Therapy

ISOPLEXIS ACQUIRED A LARGE PORTFOLIO OF DNA AND RNA SEQUENCING TO ENABLE INTEGRATED SINGLE-CELL SEQUENCING AND PROTEOMIC SOLUTIONS

IsoPlexis | May 26, 2021

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadma...

Read More
news image

Medical

INVEST ONTARIO SUPPORTS NEW BIOMANUFACTURING FACILITY IN HAMILTON

Invest Ontario | April 01, 2022

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Ha...

Read More
news image

Cell and Gene Therapy

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More